To evaluate the clinical impact of early administration of glycoprotein IIb/IIIa agents (IIb/IIIa agents) in the context of a dedicated hub and spoke network allowing very prompt pharmacological/mechanical interventions.
Introduction
Primary percutaneous coronary intervention (PPCI) is the preferred approach for re-establishing coronary perfusion in ST-elevation myocardial infarction (STEMI) when delivered in a timely fashion and in centres where appropriate facilities are available. 1 Nevertheless, in many geographical areas, logistic considerations make it difficult to perform PPCI within the recommended 90 min from the first medical contact. 2 The thrombus disaggregating effect of glycoprotein IIb/IIIa agents (IIb/IIIa agents) reduces the pre-PPCI thrombus burden, favours earlier culprit vessel reperfusion, and reduces the peri-procedural distal embolization. 3 -5 Randomized studies 4, 6 and a meta-analysis 7 showed that IIb/IIIa agents therapy can improve the angiographic and clinical results of PPCI. Other studies showed that pre-treatment with IIb/ IIIa agents (for 10-60 min) is associated with an initial TIMI 2-3 flow ranging from 35 to 55%. 8 -17 Owing to the delays encountered in many real-world settings, early administration of IIb/IIIa agents was proposed. However, the currently published randomized trials that endeavoured to evaluate this strategy showed conflicting angiographic and clinical results. 8 -21 We conducted a single-centre registry study (set in a hub and spoke STEMI network) to evaluate the effectiveness of a strategy of early administration of IIb/IIIa agents compared with the traditional (delayed) administration strategy.
Methods Study design and setting
This retrospective cohort study (conceived in accordance with the principles of the most recent revision of the Declaration of Helsinki) was based on the database (at S. Orsola-Malpighi Hospital) of one of the two centralized PCI centres participating in the 'Bologna STEMI hub and spoke network model'. 22 -25 Both centralized PCI intervention laboratories in the Province of Bologna (3702 km 2 , 950 000 inhabitants) are available at short notice on a 24 h basis within their hub-and-spoke catchment zones (containing a total of 10 peripheral hospitals without PCI facilities). Since June 2003, STEMI patients who call the '118 Emergency Medical Service' from a location within about 90 min' drive from a PCI centre are directly transported to the interventional laboratory after pre-hospital, ambulancetelemedicine diagnosis (thus bypassing the emergency department and the coronary care unit). 22 Patients who present at the emergency department of a PCI centre (spontaneously or taken by ambulances not equipped for pre-hospital triage) are directly transferred to the interventional laboratory on diagnosis of STEMI. Patients admitted to the spoke centres of the STEMI network are transported to the nearest interventional laboratory on diagnosis of high-risk STEMI, although non-high risk patients generally receive thrombolytic treatment, some may also be directly referred to PPCI at the clinicians' discretion. (Of note, patients who call the emergency service from locations .90 min drive from the interventional laboratory receive pre-hospital thrombolytic treatment.) The database used for the present study contains demographic information and comprehensive clinical, ECG, and procedural data concerning STEMI patients treated by PCI at the S. Orsola-Malpighi intervention laboratory. This prospectively compiled registry was approved by the Ethics Committees of the S. Orsola-Malpighi Hospital.
Eligibility criteria
The main inclusion criterion for this analysis was PPCI treatment associated with IIb/IIIa agent administration due to STEMI within 12 h of self-reported onset of symptoms from 2003 (when systematic use of PCI for STEMI patients was introduced) through 2006. Patients pretreated with thrombolysis were excluded. There were no restrictions based on age, sex, or clinical status. Informed consent for PCI, participation in the study protocol and anonymous publication of scientific data, was systematically sought whenever possible.
Outcome measures
Comparisons were made between those patients who received early IIb/IIIa agents administration in hub/spoke centre emergency departments or during ambulance transfer ('early administration group') and patients submitted to the traditional delayed strategy of IIb/IIIa agents administration directly in the catheterization laboratory ('late administration group'). The main clinical outcome measure was longterm freedom from death/re-infarction. A decision to perform subgroup analysis of patients with Killip class .1 and with TIMI risk index .25 (corresponding to the median value of the study population) was taken before the analysis.
Primary percutaneous coronary intervention protocol
Before arriving at the catheterization laboratory, all patients received aspirin (250 mg i.v.) and unfractioned heparin (5000 IU i.v. 
Angiographic analysis and definitions
Quantitative coronary angiography was analysed by experienced site investigators blind to all data apart from the coronary angiogram. Culprit vessel TIMI flow grades were assessed before and after PPCI. Stratification of patients into 'low risk' and 'non-low risk' subsets was based on the presence of at least one of the main risk profile criteria proposed by TIMI investigators (age !70 years, anterior STEMI, heart rate !100 b.p.m. on admission). 26 TIMI risk index was calculated using the equation: 27 [heart rate in b.p.m. Â (age in years/10) 2 ]/systolic blood pressure in mmHg. Cardiogenic shock (secondary to left or right ventricular dysfunction) was defined as a persistent systolic blood pressure ,90 mmHg (recorded in the catheterization laboratory before PPCI or aortic balloon pump implantation), unresponsive to i.v. fluid administration, or requiring vasopressor agents to maintain systolic pressure !90 mmHg. 28 Major bleeding was defined as the occurrence of intracranial or retroperitoneal bleeding or clinical signs of haemorrhage (including imaging), accompanied by a .5 g/dL drop in haemoglobin. Recurrent myocardial infarction was defined as a new increase in the creatinine kinase MB fraction to less than two times the normal upper limit, accompanied by chest pain and/or ECG changes. In-hospital events were: overall mortality, recurrent myocardial infarction, target vessel revascularization, stroke, and major bleeding. Longterm major cardiovascular events (MACE) were: overall mortality, recurrent myocardial infarction, and target vessel revascularization. Pain-to-balloon time (total ischaemic time) was defined as the interval (in min) between onset of symptoms and first balloon dilatation. Although left ventricular angiography was not performed, all patients received two-dimensional echocardiographic evaluations in the first 24 h after PPCI to assess left and right ventricular ejection fractions and exclude mechanical complications.
Ascertainment of events
For all patients, follow-up was closed on 30 September 2007. In-hospital outcome data were obtained from the main database, and by telephoning the peripheral hospitals to which patients had been transferred (as systematically recorded on the database). Long-term outcomes were ascertained by the Emilia-Romagna Regional Health Agency from codified Hospital Discharge Records (obligatorily archived for all public/private Italian hospitals) and Municipal Civil Registries. Hospital records were reviewed for additional information whenever deemed necessary.
Statistical analysis
Continuous data were expressed as mean + SD or median (25th-75th percentiles), as appropriate, and categorical data as counts (percentages). Group comparisons of categorical variables were conducted using the x 2 test with Yates correction. The two-tailed Student's t-test was used to compare normally distributed continuous variables. Comparisons of non-normally distributed variables were conducted using the Mann-Whitney rank sum test. Estimated longterm outcome measures of the early and late IIb/IIIa agents administration groups were assessed by the Kaplan-Meier method and compared using the log-rank test. Cox proportional-hazard regression analysis was used to assess whether early IIb/IIIa agents administration was an independent predictor of long-term death/re-infarction (primary outcome measure) in the overall study population and in the pre-specified patients sub-groups (TIMI risk index .25 and Killip class . 
Table1
Patients' clinical characteristics and treatment delays (determined at catheterization laboratory arrival) 
Results

Study population
During the study period, 1357 patients underwent PPCI at our institution within 12 h of symptoms without thrombolysis pretreatment: of these, 1124 (83%) were treated with IIb/IIIa agents and were included in the present analysis. Early IIb/IIIa agents administration was performed in 380 (34%) patients ('early administration group'), whereas the remaining 744 patients received IIb/ IIIa agents in the catheterization laboratory immediately before PPCI ('late administration group'). Table 1 summarizes patients' clinical characteristics and risk factors according to the two treatment groups. In both groups of patients, pre-hospital triage accounted for 30% of referrals (referral from spoke hospitals was more common in the early administration group, and PPCIcentre referral was more frequent in the late administration group). In line with these referral route distribution differences, the early administration group had somewhat longer ECG-tolaboratory and ECG-to-balloon times. Median pain-to-balloon time was 3 h in both groups (13 min longer in the early administration group). Regarding drug exposure time, the interval between IIb/IIIa agents administration and PPCI was on average 58 min longer in the early administration group; at PPCI, patients in the early administration group had a slightly lower mean heart rate, higher mean systolic pressure, and consequently a lower median TIMI risk index value ( Table 1) . Table 2 summarizes patients' angiographic and procedural characteristics in the two treatment groups.
In-hospital findings
Pre-PPCI vessel patency was more frequent in the early administration group in terms of both TIMI Grade 3 (64/380, 17% vs. 81/744, 11%; P ¼ 0.006) and 2-3 flow (128/380, 34% vs. 173/ 744, 23%; P ¼ 0.0001) but no difference was apparent in the frequency of post-PPCI TIMI Grade 3 flow (338/380, 89% vs. 647/ 744, 87%; P ¼ 0.51) or early left ventricular ejection fraction, as echo-detected within 24 h of PPCI (45 + 11 vs. 45 + 12%; P ¼ 0.71). Table 3 reports frequencies of in-hospital events according to treatment, accompanied by univariate odds ratios for early administration, which showed a (non-significant) 43% reduction in in-hospital mortality. Notably, early administration showed no sign of being associated with excess major bleeding. Favourable associations in terms of reduced in-hospital mortality and adverse events (i.e. death, re-infarction, target vessel revascularization, stroke, or major bleeding) tended to be more apparent within 'high-risk' subgroups (TIMI risk index .25 or Killip class .1; Figure 1 ). At discharge, similar rates of concomitant medications were prescribed in both study groups: b-blockers were given in 93% of both the early (338/364) and late (643/691) IIb/IIIa agents administration groups (P ¼ 0.99), statins in 57% of both the early (210/364) and late (394/691) IIb/IIIa agents administration groups (P ¼ 0.96), and angiotensin-converting enzyme-inhibitors in respectively the 84% (306/364) and 82% (568/691) of the early and late IIb/IIIa agents administration groups (P ¼ 0.50).
Long-term outcome
Outcomes were ascertained for 1121 (99.7%) patients. Figure 2 reports Kaplan -Meier curves in the overall study population according to IIb/IIIa treatment strategy. During a median follow-up of 20 months (25th -75th percentile, 13-32), the early administration group showed lower estimated 2 year rates of all-cause mortality/re-infarction (17 vs early administration (n ¼ 175) showed remarkably lower 2 year rates of death/re-infarction (23 vs. 33%; P ¼ 0.02), overall mortality (16 vs. 25%; P ¼ 0.02), and MACE (30 vs. 39%; P ¼ 0.04) (Figure 3 ). Among patients with Killip class .1 (n ¼ 265), the 2 year rates were 26 vs. 49% (P ¼ 0.001) for mortality/re-infarction; 21% vs. 39% (P ¼ 0.006) for overall mortality; 30% vs. 54% (P ¼ 0. 
Discussion
This study, set in a highly organized hub and spoke STEMI network, 22 -25 regards unselected (and therefore mainly high risk) patients who underwent rapid IIb/IIIa agents administration and PPCI (coupled with a rather short average reperfusion time).
The results suggest that a strategy of very early initiation of IIb/ IIIa agents may indeed confer long-term clinical benefits in high-risk patients without any excess risk of major bleeding in hospital. The thrombus disaggregating effects of IIb/IIIa agents can reduce the Figure 1 In-hospital overall mortality and adverse events (defined as occurrence of any of the following events: overall mortality, re-infarction, target vessel revascularization, stroke, major bleeding) evaluated in high-risk patients sub-groups according to the IIb/IIIa treatment strategy.
. pre-PPCI thrombus burden, favouring earlier culprit vessel reperfusion 3 -5 and, in line with previously reported studies, 8 -19 early administration of IIb/IIIa agents in our data was associated with higher proportions of patients achieving initial TIMI Grade 2-3 and 3 flow. Observational studies indicate that spontaneous initial TIMI 3 flow is associated with improved myocardial salvage Figure 3 Kaplan-Meier curves for TIMI risk index .25 sub-group (n ¼ 587) according to primary percutaneous coronary intervention IIb/ IIIa facilitation strategy: (A) overall mortality, (B) mortality/re-infarction, and (C) major cardiovascular events.
Long-term effectiveness of early administration of IIb/IIIa agents and survival in STEMI patients. 29, 30 Early administration of IIb/IIIa agents is an attractive concept, the potential of which remains to be fully explored, at least in high-risk patients. A subgroup analysis of the ADMIRAL trial 31 first suggested that abciximab might exert greater clinical efficacy when administered before arrival in the catheterization laboratory. Several small randomized studies 8 -17 Figure 4 Kaplan -Meier curves for Killip class .1 sub-group (n ¼ 265) according to primary percutaneous coronary intervention IIb/IIIa facilitation strategy: (A) overall mortality, (B) mortality/re-infarction, and (C) major cardiovascular events.
of mainly non-high-risk patients showed that early IIb/IIIa agents administration can improve important surrogate endpoints. However, these studies were underpowered to test the clinical efficacy of the pharmacological improvements in vessel patency. Notably pooled analyses of randomized trials 32 -35 showed conflicting results and the recently concluded FINESSE trial 20 failed to detect clinical benefits from IIb/IIIa agents facilitation therapy. In our peculiar hub and spoke STEMI network setting, early administration of IIb/IIIa agents was associated with a substantial (26%) crude reduction in the long-term risk of death/re-infarction (accompanied by sizable reductions in long-term mortality and MACE) which also reached significance at Cox proportional hazards analysis. Remarkably, the favourable associations appeared more pronounced in high-risk subgroups (TIMI risk index .25, Killip class .1). These findings should be interpreted in the context of a high-risk population submitted to timely treatment in terms of both pharmacological administration and mechanical revascularization. The observation that outcome benefits appeared to occur more frequently in patients at higher risk may not be altogether surprising in the light of studies of conventional (i.e. non-early) IIb/IIIa agents administration: the only controlled trial where survival benefits were recorded allowed enrolment of highrisk STEMI patients; 36 furthermore, some evidence of clinical benefit also emerged in a non-randomized study focusing on patients with cardiogenic shock. 37 Notably, the American
College of Cardiology/American Heart Association guidelines state that a strategy of facilitated PCI 'holds promise' (as a class IIb indication) in higher risk patients when PCI is not immediately available. 38 In our STEMI network (inaugurated in 2003), implementation of standardized protocols allows fast inter-hospital transfers and-in the case of telemedicine-guided pre-hospital triage-emergency department bypass. 22 -25 In a significant number of our facilitated patients, IIb/IIIa agents administration and mechanical revascularization were completed in the early phase of ischaemia (within 3 h from the onset of pain): in other words, within the so-called 'golden window' when the clot is less resistant and myocardial salvage-and therefore the potential for clinical benefit-may be substantial. 39 A 55-year-old Caucasian man presented with a rapid atrial fibrillation which was controlled by Digoxin with spontaneously converting to sinus rhythm. He had history of diabetes. Physical examination showed an infected wound at one toe of the right foot.
There was no electrolyte abnormality, and cardiac-specific enzymes were normal. Conventional echocardiography revealed a mild mitral regurgitation and a suspected cavity in the left atria. Transoesophageal echocardiography and magnetic resonance imaging revealed a large cavity (5 cm of diameter) attached to the atrial side of the posterior leaflet of the mitral valve (Panels A-C), communicating with the ventricle via a single neck. Doppler colour imaging demonstrated blood flow entering the cavity from the left ventricle in systole and returning from the cavity to the ventricle in diastole (Panels D and E). Our first hypothesis was a mitral endocarditis with abscess, but the patient remained asymptomatic with no clinical criteria for infective endocarditis and no septic peripheral emboli. All the cultures were negative.
Coronary angiography showed normal coronary arteries.
The diagnosis of submitral aneurysm was made, and the patient was referred to surgery. The aneurysm was resected (Panel F) and the orifice was repaired with a Dacronw patch. The post-operative course was uneventful. The pathological examination does not suggest an inflammatory aetiology.
Submitral aneurysm is a relatively unknown cardiac pathology, described predominantly in black Africans. They occur in constant anatomic positions, under the posterior leaflet of the mitral valve. It should be differentiated from left ventricular false aneurysm, caused by myocardial necrosis. Atrial fibrillation has not been previously reported in association with submitral aneurysm. 
